Anti-tubular basement membrane disease (aTBM disease) produces T cell-mediated interstitial nephritis in SJL mice after immunization with renal tubular antigen. Initial mononuclear infiltrates appear in vivo after several weeks, with the subsequent progression to renal fibrosis and end stage renal disease over many months. We have analyzed the fine
Introduction
Recent advances in immunology have facilitated the examination of autoimmune T cell repertoires (1) (2) (3) , and have provided important insights into the molecular basis of autoreactive T cell recognition of target antigenic immunodominant epitopes (3 -7) . Analyses of T cell receptor (TCR)1 variable (V) region genes used by autoreactive T cells in animal models of autoimmunity (3, (8) (9) (10) (11) (12) as well as in human autoimmune diseases (3, [13] [14] [15] [16] , have revealed numerous instances of autoreactive T cell repertoires containing the preferential use of individual VP3 region genes. Such work has resulted in successful, specific anti-VP gene immunotherapy (2, 3, 6, 17, 18) . Despite these findings, there remains some controversy about the extent of restricted V region gene repertoires in autoimmune diseases (16) , especially in systems lacking good information about epitope recognition.
We have been studying the cellular and molecular mechanisms involved in the expression of autoimmune interstitial nephritis ( 19, 20) . In one such model, anti-tubular basement membrane (aTBM) disease in the SJL mouse, autoimmune interstitial nephritis is induced by immunizing susceptible animals with a rabbit renal tubular antigen preparation in complete Freund's adjuvant (RTA/CFA) (21) . Animals develop nonpathogenic anti-tubular basement membrane antibodies in 7-10 d (22) , with a subsequent renal mononuclear cell infiltrate at 6-8 wk (21, 22) , that progresses to interstitial fibrosis, end stage renal disease, and death (21, 23) . The development of aTBM disease depends upon the emergence of a CD4+ helper T cell reactive to the target antigen 3M-1 (7) , which is expressed on the surface of proximal renal tubular epithelial cells (24) . These helper T cells induce the development of 3M-I-reactive CD8 + effector T cells (25, 26) , that mediate cytotoxicity and delayed-type hyper-sensitivity (DTH) , and can adoptively transfer disease to naive syngeneic recipients (26, 27) .
To further characterize the helper T cell repertoire in aTBM disease, we have set out to evaluate the peptide antigen specificity, and the selection of T cell receptor V,@ genes in CD4+ nephritogenic helper T cells.
Methods
Antigens. Rabbit renal tubular antigen (RTA) was isolated by previously published methods (28) , and emulsified at 8 mg/ml with complete Freund's adjuvant (4 mg/ml of purified protein derivative from Connaught Laboratories Ltd, Toronto, Ontario, Canada; mixed with incomplete Freund's adjuvant purchased from GIBCO BRL, Grand Island, NY) to produce RTA/CFA; 0.2 ml was injected over multiple sites.
Soluble renal tubular antigen (SRTA) was made from lyophilized RTA by collagenase digestion (29) . Peptides P1 (LLRRRHGDRRSTMSA-EVP), P2 (ASAEEQKEMEDKVTSPEKAEEA), and P3 (STMSAE-VPEAASAE) were derived from the deduced amino acid sequence of the cloned cDNA for 3M-1 (7, 30) and were synthesized by standard peptide synthetic techniques (31) , and HPLC purified (University of Pennsylvania peptide synthesis facility, Philadelphia, PA, and Research Genetics, Huntsville, AL).
Immunization. SJL mice (H-2') 4-6 wk of age (Jackson Laboratory, Bar Harbor, ME) were immunized with RTA/CFA in multiple sites to get aTBM disease (21) . Isolation and maintenance of T cell lines and clones. T cell lines were established by standard methods (26, 32) . Immune cells harvested from draining lymph nodes of SJL mice 10-14 d after immunization were placed in a 24-well culture plate in 2 ml of complete T cell media containing 20 ,g/ml of appropriate antigen and cultured at 370C in 5% CO2 for 4 d. Complete T cell media consists of RPMI 1640 (JRH Biosciences, Lenexa, KS), supplemented with 10% complement-depleted fetal calf serum, 5% NCTC (Whittaker Bioproducts, Walkersville, MD), 2 x I0-5 M 2-mercaptoethanol, glutamine, and antibiotics. After 4 d, and then weekly thereafter, the cells were harvested and placed in fresh media containing antigen, 20% MLA 144 supernatant as a source of IL-2 and other growth factors (33) , and 3-5 x 106 irradiated (2,500 rads) syngeneic splenic feeder cells (26) . T cell lines were cloned twice by limiting dilution in 96-well plates (26) , and then expanded and passaged weekly as described above. Some (34) . First strand cDNA was made with mMLV (GIBCO BRL) and oligo-dT (34, 35) . 500 ng of the resultant RNA/cDNA was used in a 100 X polymerase chain reaction, containing lox of lOx buffer (Perkin-Elmer Cetus, Ex Effector cell induction assay. The assay was performed as previously described (25, 26, 43) . Briefly, 30-250 X 106 nonirradiated syngeneic splenocytes were incubated with 20% MLA supernatant, 20 ug/ml of antigen, and 20% T cell clone supernatant (taken from the end of a 7-d culture) in a T25 or T75 culture flask (Falcon; Becton Dickinson Labware, Lincoln Park, NJ) for 5 d at 370C in 5% CO2. At the end of the culture period, the induced effector T cells were washed extensively in standard media followed by PBS, and were used for local adoptive transfer of delayed-type hypersensitivity (DTH) or subcapsular transfer.
Local adoptive transfer of DTH. This assay has been previously reported in detail (25, 26) . Induced effector cells, as described above, were resuspended in PBS at 2.0 x 10' cells/ml, with or without antigen (10 pg/ml), and 25X of each cell preparation was injected into the hind footpads of recipient naive SJL mice (three per group). Footpad swelling as an index of DTH was measured 48 h later using a spring-loaded engineer's micrometer (Schlesingers for Tools, Brooklyn, NY). The magnitude of swelling was expressed as the mean increment between the antigen-challenged footpad and that injected with PBS in inches x 10-3+SEM. All measurements were performed by an individual blinded to the experimental protocol.
Subcapsular transfer experiments. Naive syngeneic mice were anesthetized and 108 induced effector lymphocytes (derived from an effector cell induction as described above) in 75A of PBS were injected under the kidney capsule with a 30-gauge needle. After 7 d, the kidneys were harvested, fixed in 10% buffered formalin, and stained with hematoxylin and eosin. The stained sections were interpreted by an investigator blinded to the experiment (25, 43) . TCR VP3 gene analysis by cDNA amplification. Total RNA was prepared from Lympholyte-M'-treated T cell clones or snap frozen whole spleen by the guanididium isothiocyanate method (34) . Oligo dT-primed first-strand synthesis was performed with mMLV reverse transcriptase (34, 35) . PCR was performed in lOOX total volume, as described above, using 750 ng of RNA/cDNA template, 40 (34, 48) .
A cDNA product encoding the T cell receptor Vl region from one of the T cell clones was also obtained using anchored PCR (35) . Briefly, first strand synthesis was performed using mMLV and a specific 3' TcR C,3 antisense primer C/3dan, 5 'TCAGGAATTCTTTClTTl GA3' (49).
The cDNA was then G tailed, and amplifications were performed using an internal 3' primer, PH12, and a 5' poly C primer (35) .
Southern hybridization. PCR products were transferred to a Zetabind (Cuno, Inc., Meriden, CT) membrane by capillary action using standard techniques, denatured for 10 min with 0.4 M NaOH, and UV crosslinked (Stratalinker; Stratagene, La Jolla, CA). Prehybridization and hybridization were performed as previously described (34) Cloning and sequencing of the VJ PCR products. V,/ PCR products were cloned into the TA cloning system (Invitrogen, La Jolla, CA). DNA was prepared for sequencing using the dideoxy chain termination (34, 35 Sequence comparison of T cell receptor deduced amino acid sequences. 52 random murine TcR,6 junctional sequences were obtained from the October 15, 1993 Entrez:Sequences program (NCBI, Bethesda, MD) using the keywords "T-cell receptor" and "T-cell receptor beta."
Only sequences encoding functional TcRs in which the V,//Df and D,6/J,/ junctions were identified were analyzed. Statistical comparisons were done using X2 analysis.
Results
Selection of potential antigenic peptides. Two potential antigenic epitopes, P1 and P2 were chosen from the deduced amino acid sequence of the cloned cDNA for the target antigen of aTBM disease, 3M-1 (7) , using a software algorithm integrating a variety of determinants of protein conformation to assist in the prediction of peptide immunogenicity (50) (Fig. 1) . P1 is an 18-amino acid peptide, separated by two amino acids from the 22-residue peptide, P2. We later chose a third, overlapping candidate 14 residue peptide, P3 (Fig. 1) , that starts at a potential Cathepsin B site (after Arg-Arg), because Cathepsin B Previous work by our laboratory has shown that CD4+ T cells overgrow all other T cell subtypes when isolated by our methods (26) . The CD4 , CD8-, TcR a13+ phenotype of each T cell clone was confirmed with FACS analysis using specific FITC-conjugated antibodies. A representative analysis of one clone is shown is Fig. 2 . All of the isolated T cell clones expressed this identical phenotype.
Cytokine expression profile of T cell clones. The reverse transcription polymerase chain reaction (RT-PCR) was initially used to analyze the cytokine profile of each T cell clone. Pilot studies were done using total spleen RNA to determine optimal parameters for the detection of each transcript, and to show that amplification was in the linear range without evidence of plateau (data not shown). The cytokine profile of two representative T cell clones is shown in Fig. 3 A, and reveals appropriate sized products for yIFN and IL-2, but not IL-4, while all three transcripts are found in splenic RNA. All of the clones exhibited the same cytokine transcript profile. Confirmation of IL-2 production by selected Con A stimulated T cell clones is shown in Fig. 3 B. Supematants induced proliferation of HT-2 cells that was almost completely blocked by anti-IL-2 antibody, but was unaffected by a polyclonal, control, isotype matched, mouse IgM. All clones tested behaved in a similar fashion (data not shown).
Antigen specificity as determined by local adoptive transfer of DTH. We initially chose to determine the antigen specificity of each clone using a functional assay, the ability to induce an antigen-specific, DTH-producing effector cell population. Each clone was tested with SRTA, PI, P2, and P3. As can be seen in (Fig. 7 A, left) . Surface expression of V,614 was confirmed by FACS ( Fig. 7 A, right) . Similarly, clone M36.9.1 expresses Vf7 (Fig. 7 B) . The VP genes used by all 10 T cell clones are shown in Fig. 8 . The VP genes expressed by six of the clones (those expressing V63, 7, and 14) were confirmed by FACS. No antibodies for V,/1, 10, 15, and 16 were available. Six VP genes were used by the eight different P3-reactive T cell clones, with three clones, M33.25.6, M31.1, and M31B.3., using V,314. The two P2-reactive clones used V,67 and Vfil (Fig. 8) . To assess the baseline frequency of V,63, V/37, and V314 within the peripheral T cell repertoire of the SJL mouse, we performed FACS analysis on freshly isolated splenic lymphocytes derived from unimmunized animals. Double labeling experiments using a PE-conjugated aCD4 antibody, and FITC-conjugated aVP antibodies revealed that Vf33, V/37, and Vf314 make up 5%, 5%, and 6.5% of the CD4+ T cell population, respectively (data not shown). (25, 43) , and confirmed in selected clones through the use of a proliferation assay (24, 26) . All clones stimulated weekly with SRTA or P1 specifically reacted to the P3 peptide, and not to P2, suggesting that these T cell clones recognize a core sequence of eight amino acids (STMSAEVP, bold letters in Fig. 1) . Interestingly, this core sequence, as well as the entire P3 epitope, is anionic, and contains no positively charged residues (Fig. 1) . Future work involving the elution of peptide from MHC II molecules (57) , and a systematic evaluation of T cell reactivity to overlapping and mutated peptides, will be required to potentially identify the optimal peptide size, and the importance of individual residues in the recognition of this immunodominant epitope by the different T cell clones.
We also isolated two CD4+ ThI T cell clones which recognized the P2 peptide in vitro, but were unable to recognize the intact SRTA from which this peptide was derived. We find it curious that these T cell clones, isolated from animals immunized with RTA, can recognize the P2 peptide, but not the intact antigen. Although the explanation for this phenomenon is not readily apparent, the relative difficulty in isolating these clones (we were only able to isolate two) suggests that the target antigen of aTBM disease, 3M-1, is only rarely processed into P2 (or a peptide containing a significant portion of P2) by I-A' antigen presenting cells in the SJL mouse.
The relevance of P3 (but not to P2) to the development of aTBM disease was demonstrated through showing that the clones reactive to P3 were able to transfer disease to naive recipients, while a P2-reactive clone was not. In sum, these findings suggest that CD4 +, ThI helper T cells derived from the peripheral lymphoid system of animals immunized to produce aTBM disease, and directed towards an immunodominant epitope contained within the P3 peptide, are nephritogenic. Interestingly, both the aTBM antibody response and the CD8 + effector T cell response are also directed at P1 (7, 27 ) (reactivity towards P3 has not been tested), confirming the importance of this antigenic epitope in the pathogenesis of aTBM disease. Although our results demonstrate a single immunodominant peptide epitope relevant to the development of disease, it is possible that other, secondary, cryptic epitopes emerge within the kidney as the disease process progresses (58) . Studies evaluating the peptide specificity of nephritogenic T cells derived from diseased organs will be required to address this issue.
Analysis of the TcR VP6 genes used by the P3 epitopespecific T cell clones revealed the use of several VP genes, with a recurrent use (3/8) of V/314. This 38% incidence of Vf14 expression by P3-reactive clones, compared with 6.5% of the peripheral CD4+ T cell population, provides evidence for the preferential use of the V/314 gene by the nephritogenic T cell clones. Collectively, our findings suggest that the anti-3M-1 TCR repertoire is oligoclonal. Whether these findings are representative of the TcR repertoire within diseased organs is an area of ongoing investigation. It should be noted however, that interpretation of TCR gene usage analyses in diseased whole organs is often hampered by the lack of definition of peptide specificity (16) , and results may not correlate with findings derived from peptide specific T cell clones (16) .
Perhaps more intriguing than the oligoclonality of the TCR response is the similarity of the deduced amino acid sequences across the V,63DP3/J,3 junction. Based initially on comparative analyses between immunoglobulin and TcR sequences (59, 60) , and later confirmed by statistical (61) , and mutational (62) (63) (64) analyses, the V,6/Df3/J/3 junction of the TcR in CD4 + cells has been proposed to constitute the putative CDR3 region, and thus make direct contact with its peptide/MHC class II ligand.
The statistically significant overrepresentation (compared with a random set of functional TcRQ chains) of a small nonpolar amino acid at the D,6/J,6 junction, and an Arg or Lys at the V,8/Dp junction, both determined by N region additions or deletions, suggests that these residues may be important in the specific recognition of P3. Additionally, the CDR3 region of all of the P3-reactive clones is neutral or cationic (Arg/Lys), with a distinct lack of negative charges (Glu in position 101 of M36.6.1 is the only one, and is counteracted by an adjacent Arg, Fig. 8 ), suggesting a direct interaction with the anionic P3 peptide. Analogous findings have been noted in another model of autoimmune renal injury (8) . The precise determination of the role played by individual residues within the CDR3 in the specific recognition of the P3/MHC class II complex will require a mutational analysis of the TCR. Finally, the sequence of the TCR a chain needs to be defined before any definitive statements regarding the molecular basis of P3 recognition by autoreactive T cells can be made. Based on these experiments, however, it may be possible to direct specific immunotherapy at a common epitope within the TCR/3 CDR3 region of nephritogenic, P3-reactive T cells.
